Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 68, Issue 3, Pages 249-258Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-011-1120-6
Keywords
Vorapaxar; SCH 530348; PAR-1 antagonist; Pharmacokinetics; Pharmacodynamics; Platelet aggregation; Thrombin receptor antagonist
Categories
Funding
- Merck, Whitehouse Station, NJ, USA
- Merck
Ask authors/readers for more resources
Purpose The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers. Methods and results In two randomized, placebo-controlled studies, subjects received either single ascending doses of vorapaxar (0.25, 1, 5, 10, 20, or 40 mg; n = 50), multiple ascending doses of vorapaxar (1, 3, or 5 mg/day for 28 days; n = 36), a loading dose (10 or 20 mg) followed by daily maintenance doses (1 mg) for 6 days (n = 12), or placebo. Single 20- and 40-mg doses of vorapaxar completely inhibited thrombin receptor activating peptide (TRAP)-induced platelet aggregation (>80% inhibition) at 1 h and sustained this level of inhibition for >= 72 h. Multiple doses yielded complete inhibition on Day 1 (5 mg/day) and Day 7 (1 and 3 mg/day). Adverse events were generally mild, transient, and unrelated to dose. Conclusion Vorapaxar provided rapid and sustained dose-related inhibition of platelet aggregation without affecting bleeding or clotting times.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available